Abstract

BackgroundA cohort of routine care rheumatoid arthritis (RA) patients in sustained remission had biological disease-modifying anti-rheumatic drugs (bDMARDs) tapered according to a treatment guideline. Little is known about predictors of...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
THU0096 Multi-biomarker disease activity (MBDA) is associated with the progression of structural bone damage in rheumatoid arthritis patients in remission
S Finzel ... J Fogagnolo Cobra
Annals of the Rheumatic Diseases | VOL. 76
S Finzel, et. al.S Finzel ... J Fogagnolo Cobra
01 Jun 2017
OP0264 COST-UTILITY OF A PROGRESSIVE SPACING OF TOCILIZUMAB OR ABATACEPT IN PATIENTS WITH RHEUMATOID ARTHRITIS IN SUSTAINED REMISSION: A MEDICO-ECONOMIC ANALYSIS OF THE TOLEDO TRIAL
B Fautrel ... L El Houari
Annals of the Rheumatic Diseases | VOL. 82
B Fautrel, et. al.B Fautrel ... L El Houari
30 May 2023
SAT0663 ABILITY OF THE MULTI-BIOMARKER DISEASE ACTIVITY SCORE TO IDENTIFY RHEUMATOID ARTHRITIS PATIENTS IN REMISSION AT RISK OF RELAPSE AFTER TNF-BLOCKER TAPERING. AN ANCILLARY STUDY OF THE STRASS TRIAL
Bruno Fautrel ... Xinyu Liu
-
Bruno Fautrel, et. al.Bruno Fautrel ... Xinyu Liu
27 May 2019
Does tenosynovitis of the hand detected by B-mode ultrasound predict loss of clinical remission in rheumatoid arthritis? Results from a real-life cohort.
Kristina Bürki ... Raphael Micheroli
Journal of ultrasonography | VOL. 22
Kristina Bürki, et. al.Kristina Bürki ... Raphael Micheroli
08 Feb 2022
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers